nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—Protein Kinase Inhibitors—Nilotinib—hematologic cancer	0.186	0.5	CiPCiCtD
Vandetanib—Protein Kinase Inhibitors—Ruxolitinib—hematologic cancer	0.186	0.5	CiPCiCtD
Vandetanib—FLT3—hematologic cancer	0.0371	0.17	CbGaD
Vandetanib—ABL2—hematologic cancer	0.033	0.151	CbGaD
Vandetanib—LCK—hematologic cancer	0.0315	0.144	CbGaD
Vandetanib—FGR—hematologic cancer	0.0281	0.129	CbGaD
Vandetanib—RET—hematologic cancer	0.0239	0.109	CbGaD
Vandetanib—PDGFRB—hematologic cancer	0.0165	0.0758	CbGaD
Vandetanib—ABL1—hematologic cancer	0.0148	0.0676	CbGaD
Vandetanib—SRC—hematologic cancer	0.0133	0.0612	CbGaD
Vandetanib—PTK6—Dasatinib—hematologic cancer	0.0121	0.0486	CbGbCtD
Vandetanib—VEGFA—hematologic cancer	0.0106	0.0487	CbGaD
Vandetanib—RIPK2—Dasatinib—hematologic cancer	0.00876	0.0351	CbGbCtD
Vandetanib—LTK—Ruxolitinib—hematologic cancer	0.00816	0.0327	CbGbCtD
Vandetanib—STK35—Dasatinib—hematologic cancer	0.00696	0.0279	CbGbCtD
Vandetanib—EPHA5—Dasatinib—hematologic cancer	0.00696	0.0279	CbGbCtD
Vandetanib—ERBB3—Dasatinib—hematologic cancer	0.00696	0.0279	CbGbCtD
Vandetanib—FYN—Dasatinib—hematologic cancer	0.00696	0.0279	CbGbCtD
Vandetanib—BMPR1B—Dasatinib—hematologic cancer	0.00696	0.0279	CbGbCtD
Vandetanib—PLK4—Ruxolitinib—hematologic cancer	0.00683	0.0274	CbGbCtD
Vandetanib—EPHA8—Nilotinib—hematologic cancer	0.00659	0.0264	CbGbCtD
Vandetanib—TEK—Nilotinib—hematologic cancer	0.00659	0.0264	CbGbCtD
Vandetanib—ABCG2—hematologic cancer	0.00655	0.03	CbGaD
Vandetanib—RET—Ruxolitinib—hematologic cancer	0.0059	0.0236	CbGbCtD
Vandetanib—EPHA8—Dasatinib—hematologic cancer	0.00582	0.0233	CbGbCtD
Vandetanib—MAP4K5—Dasatinib—hematologic cancer	0.00582	0.0233	CbGbCtD
Vandetanib—YES1—Dasatinib—hematologic cancer	0.00582	0.0233	CbGbCtD
Vandetanib—FGR—Nilotinib—hematologic cancer	0.00569	0.0228	CbGbCtD
Vandetanib—EPHB6—Nilotinib—hematologic cancer	0.00503	0.0202	CbGbCtD
Vandetanib—LYN—Nilotinib—hematologic cancer	0.00503	0.0202	CbGbCtD
Vandetanib—BLK—Nilotinib—hematologic cancer	0.00503	0.0202	CbGbCtD
Vandetanib—EPHA6—Nilotinib—hematologic cancer	0.00503	0.0202	CbGbCtD
Vandetanib—FGR—Dasatinib—hematologic cancer	0.00503	0.0202	CbGbCtD
Vandetanib—ABL2—Imatinib—hematologic cancer	0.00498	0.02	CbGbCtD
Vandetanib—LCK—Imatinib—hematologic cancer	0.00453	0.0182	CbGbCtD
Vandetanib—PDGFRB—Imatinib—hematologic cancer	0.00453	0.0182	CbGbCtD
Vandetanib—ABL2—Nilotinib—hematologic cancer	0.00452	0.0181	CbGbCtD
Vandetanib—LYN—Dasatinib—hematologic cancer	0.00445	0.0178	CbGbCtD
Vandetanib—BLK—Dasatinib—hematologic cancer	0.00445	0.0178	CbGbCtD
Vandetanib—SRC—Dasatinib—hematologic cancer	0.00445	0.0178	CbGbCtD
Vandetanib—EPHB6—Dasatinib—hematologic cancer	0.00445	0.0178	CbGbCtD
Vandetanib—LCK—Nilotinib—hematologic cancer	0.00412	0.0165	CbGbCtD
Vandetanib—MAP2K5—Nilotinib—hematologic cancer	0.00412	0.0165	CbGbCtD
Vandetanib—PDGFRB—Nilotinib—hematologic cancer	0.00412	0.0165	CbGbCtD
Vandetanib—ABL2—Dasatinib—hematologic cancer	0.004	0.016	CbGbCtD
Vandetanib—MAP3K19—Ruxolitinib—hematologic cancer	0.00392	0.0157	CbGbCtD
Vandetanib—PDGFRB—Dasatinib—hematologic cancer	0.00364	0.0146	CbGbCtD
Vandetanib—MAP2K5—Dasatinib—hematologic cancer	0.00364	0.0146	CbGbCtD
Vandetanib—FMO3—Dasatinib—hematologic cancer	0.00364	0.0146	CbGbCtD
Vandetanib—LCK—Dasatinib—hematologic cancer	0.00364	0.0146	CbGbCtD
Vandetanib—ABL1—Imatinib—hematologic cancer	0.0036	0.0144	CbGbCtD
Vandetanib—MAP3K19—Dasatinib—hematologic cancer	0.00334	0.0134	CbGbCtD
Vandetanib—ABL1—Nilotinib—hematologic cancer	0.00327	0.0131	CbGbCtD
Vandetanib—ABL1—Dasatinib—hematologic cancer	0.00289	0.0116	CbGbCtD
Vandetanib—ALB—hematologic cancer	0.00286	0.0131	CbGaD
Vandetanib—BMPR1B—ovarian follicle—hematologic cancer	0.00253	0.0882	CbGeAlD
Vandetanib—ABCC1—Idarubicin—hematologic cancer	0.00227	0.00908	CbGbCtD
Vandetanib—ABCG2—Clofarabine—hematologic cancer	0.00183	0.00734	CbGbCtD
Vandetanib—ABCC1—Daunorubicin—hematologic cancer	0.0016	0.00643	CbGbCtD
Vandetanib—ORM1—Imatinib—hematologic cancer	0.00135	0.0054	CbGbCtD
Vandetanib—ABCG2—Daunorubicin—hematologic cancer	0.00107	0.0043	CbGbCtD
Vandetanib—ABCC1—Mitoxantrone—hematologic cancer	0.000974	0.00391	CbGbCtD
Vandetanib—ABCG2—Teniposide—hematologic cancer	0.000932	0.00374	CbGbCtD
Vandetanib—ABCG2—Cladribine—hematologic cancer	0.000894	0.00358	CbGbCtD
Vandetanib—ABCG2—Imatinib—hematologic cancer	0.000822	0.00329	CbGbCtD
Vandetanib—ABCC1—Epirubicin—hematologic cancer	0.000789	0.00316	CbGbCtD
Vandetanib—ABCC1—Irinotecan—hematologic cancer	0.000767	0.00307	CbGbCtD
Vandetanib—ABCG2—Nilotinib—hematologic cancer	0.000747	0.00299	CbGbCtD
Vandetanib—ABCC1—Vinblastine—hematologic cancer	0.000682	0.00273	CbGbCtD
Vandetanib—ABCC1—Vincristine—hematologic cancer	0.000671	0.00269	CbGbCtD
Vandetanib—ABCG2—Dasatinib—hematologic cancer	0.00066	0.00265	CbGbCtD
Vandetanib—ABCG2—Mitoxantrone—hematologic cancer	0.000652	0.00261	CbGbCtD
Vandetanib—ABCC1—Etoposide—hematologic cancer	0.000615	0.00246	CbGbCtD
Vandetanib—ALB—Imatinib—hematologic cancer	0.000567	0.00227	CbGbCtD
Vandetanib—ABCG2—Irinotecan—hematologic cancer	0.000513	0.00206	CbGbCtD
Vandetanib—ABCG2—Vincristine—hematologic cancer	0.000449	0.0018	CbGbCtD
Vandetanib—BLK—hematopoietic system—hematologic cancer	0.000426	0.0148	CbGeAlD
Vandetanib—ABCC1—Doxorubicin—hematologic cancer	0.000419	0.00168	CbGbCtD
Vandetanib—ABCG2—Cisplatin—hematologic cancer	0.000419	0.00168	CbGbCtD
Vandetanib—ABCG2—Etoposide—hematologic cancer	0.000411	0.00165	CbGbCtD
Vandetanib—ABCC1—Methotrexate—hematologic cancer	0.000406	0.00163	CbGbCtD
Vandetanib—PTK6—hematopoietic system—hematologic cancer	0.000403	0.014	CbGeAlD
Vandetanib—CYP3A4—Bexarotene—hematologic cancer	0.000395	0.00158	CbGbCtD
Vandetanib—ALB—Prednisone—hematologic cancer	0.000373	0.0015	CbGbCtD
Vandetanib—CYP3A4—Lomustine—hematologic cancer	0.000368	0.00147	CbGbCtD
Vandetanib—CYP3A4—Busulfan—hematologic cancer	0.000368	0.00147	CbGbCtD
Vandetanib—ALB—Irinotecan—hematologic cancer	0.000354	0.00142	CbGbCtD
Vandetanib—ABCG2—Dexamethasone—hematologic cancer	0.000338	0.00136	CbGbCtD
Vandetanib—PLK4—hematopoietic system—hematologic cancer	0.000332	0.0116	CbGeAlD
Vandetanib—CYP3A4—Thiotepa—hematologic cancer	0.000328	0.00131	CbGbCtD
Vandetanib—TYRO3—hematopoietic system—hematologic cancer	0.000312	0.0109	CbGeAlD
Vandetanib—LYN—hematopoietic system—hematologic cancer	0.00031	0.0108	CbGeAlD
Vandetanib—BLK—blood—hematologic cancer	0.000282	0.00982	CbGeAlD
Vandetanib—ABCG2—Doxorubicin—hematologic cancer	0.00028	0.00112	CbGbCtD
Vandetanib—ABCG2—Methotrexate—hematologic cancer	0.000272	0.00109	CbGbCtD
Vandetanib—PTK6—blood—hematologic cancer	0.000267	0.0093	CbGeAlD
Vandetanib—FLT3—hematopoietic system—hematologic cancer	0.000265	0.00924	CbGeAlD
Vandetanib—EPHA6—gonad—hematologic cancer	0.000256	0.0089	CbGeAlD
Vandetanib—CYP3A4—Methoxsalen—hematologic cancer	0.000255	0.00102	CbGbCtD
Vandetanib—PLK4—gonad—hematologic cancer	0.000253	0.00879	CbGeAlD
Vandetanib—LTK—lung—hematologic cancer	0.000244	0.00851	CbGeAlD
Vandetanib—CYP3A4—Bortezomib—hematologic cancer	0.000242	0.000971	CbGbCtD
Vandetanib—FLT4—hematopoietic system—hematologic cancer	0.000241	0.00839	CbGeAlD
Vandetanib—RIPK2—hematopoietic system—hematologic cancer	0.00024	0.00834	CbGeAlD
Vandetanib—TYRO3—gonad—hematologic cancer	0.000237	0.00826	CbGeAlD
Vandetanib—PTK6—lung—hematologic cancer	0.000234	0.00816	CbGeAlD
Vandetanib—IRAK4—hematopoietic system—hematologic cancer	0.000234	0.00815	CbGeAlD
Vandetanib—CYP3A4—Daunorubicin—hematologic cancer	0.000232	0.000929	CbGbCtD
Vandetanib—LTK—testis—hematologic cancer	0.000231	0.00803	CbGeAlD
Vandetanib—ERBB3—hematopoietic system—hematologic cancer	0.000229	0.00799	CbGeAlD
Vandetanib—EPHA8—testis—hematologic cancer	0.000221	0.0077	CbGeAlD
Vandetanib—PLK4—blood—hematologic cancer	0.00022	0.00766	CbGeAlD
Vandetanib—MKNK1—hematopoietic system—hematologic cancer	0.000215	0.0075	CbGeAlD
Vandetanib—PLK4—bone marrow—hematologic cancer	0.000213	0.00741	CbGeAlD
Vandetanib—RET—hematopoietic system—hematologic cancer	0.000213	0.00741	CbGeAlD
Vandetanib—FGR—hematopoietic system—hematologic cancer	0.000213	0.00741	CbGeAlD
Vandetanib—AXL—hematopoietic system—hematologic cancer	0.000212	0.00738	CbGeAlD
Vandetanib—LYN—blood—hematologic cancer	0.000206	0.00716	CbGeAlD
Vandetanib—CYP3A4—Cytarabine—hematologic cancer	0.000204	0.00082	CbGbCtD
Vandetanib—FLT3—gonad—hematologic cancer	0.000202	0.00702	CbGeAlD
Vandetanib—CYP3A4—Teniposide—hematologic cancer	0.000201	0.000807	CbGbCtD
Vandetanib—FYN—hematopoietic system—hematologic cancer	0.000198	0.0069	CbGeAlD
Vandetanib—STK35—gonad—hematologic cancer	0.000198	0.00688	CbGeAlD
Vandetanib—Erlotinib—JAK3—hematologic cancer	0.000197	0.0901	CrCbGaD
Vandetanib—TEK—hematopoietic system—hematologic cancer	0.000194	0.00675	CbGeAlD
Vandetanib—MAP4K5—hematopoietic system—hematologic cancer	0.000194	0.00675	CbGeAlD
Vandetanib—PLK4—lung—hematologic cancer	0.000193	0.00672	CbGeAlD
Vandetanib—ALB—Methotrexate—hematologic cancer	0.000187	0.000751	CbGbCtD
Vandetanib—CYP3A4—Ifosfamide—hematologic cancer	0.000186	0.000745	CbGbCtD
Vandetanib—EPHA6—testis—hematologic cancer	0.000184	0.00642	CbGeAlD
Vandetanib—PLK4—testis—hematologic cancer	0.000182	0.00634	CbGeAlD
Vandetanib—Afatinib—LCK—hematologic cancer	0.00018	0.0822	CrCbGaD
Vandetanib—YES1—hematopoietic system—hematologic cancer	0.000179	0.00623	CbGeAlD
Vandetanib—CYP3A4—Imatinib—hematologic cancer	0.000178	0.000712	CbGbCtD
Vandetanib—BMPR1B—lung—hematologic cancer	0.000178	0.00618	CbGeAlD
Vandetanib—MAP3K19—lung—hematologic cancer	0.000178	0.00618	CbGeAlD
Vandetanib—STK10—hematopoietic system—hematologic cancer	0.000177	0.00618	CbGeAlD
Vandetanib—FLT3—blood—hematologic cancer	0.000176	0.00612	CbGeAlD
Vandetanib—SRC—hematopoietic system—hematologic cancer	0.000172	0.00599	CbGeAlD
Vandetanib—TYRO3—testis—hematologic cancer	0.000171	0.00595	CbGeAlD
Vandetanib—FLT3—bone marrow—hematologic cancer	0.00017	0.00592	CbGeAlD
Vandetanib—BLK—lymph node—hematologic cancer	0.000169	0.00588	CbGeAlD
Vandetanib—ABL2—blood—hematologic cancer	0.000168	0.00584	CbGeAlD
Vandetanib—BMPR1B—testis—hematologic cancer	0.000168	0.00583	CbGeAlD
Vandetanib—MAP3K19—testis—hematologic cancer	0.000168	0.00583	CbGeAlD
Vandetanib—CYP3A4—Ruxolitinib—hematologic cancer	0.000167	0.00067	CbGbCtD
Vandetanib—LTK—lymph node—hematologic cancer	0.000167	0.00582	CbGeAlD
Vandetanib—MKNK1—gonad—hematologic cancer	0.000164	0.0057	CbGeAlD
Vandetanib—CYP3A4—Nilotinib—hematologic cancer	0.000161	0.000647	CbGbCtD
Vandetanib—AXL—gonad—hematologic cancer	0.000161	0.00561	CbGeAlD
Vandetanib—CYP3A4—Vinorelbine—hematologic cancer	0.00016	0.000641	CbGbCtD
Vandetanib—FLT4—blood—hematologic cancer	0.00016	0.00556	CbGeAlD
Vandetanib—RIPK2—blood—hematologic cancer	0.000159	0.00553	CbGeAlD
Vandetanib—KDR—hematopoietic system—hematologic cancer	0.000158	0.00551	CbGeAlD
Vandetanib—IRAK4—blood—hematologic cancer	0.000155	0.0054	CbGeAlD
Vandetanib—FLT4—bone marrow—hematologic cancer	0.000154	0.00538	CbGeAlD
Vandetanib—FLT3—lung—hematologic cancer	0.000154	0.00537	CbGeAlD
Vandetanib—RIPK2—bone marrow—hematologic cancer	0.000154	0.00535	CbGeAlD
Vandetanib—VEGFA—bone marrow—hematologic cancer	0.000153	0.00533	CbGeAlD
Vandetanib—STK35—lung—hematologic cancer	0.000151	0.00526	CbGeAlD
Vandetanib—IRAK4—bone marrow—hematologic cancer	0.00015	0.00522	CbGeAlD
Vandetanib—Erlotinib—FLT3—hematologic cancer	0.000149	0.0683	CrCbGaD
Vandetanib—MAP4K5—gonad—hematologic cancer	0.000147	0.00513	CbGeAlD
Vandetanib—ABL2—lung—hematologic cancer	0.000147	0.00512	CbGeAlD
Vandetanib—CYP3A4—Triamcinolone—hematologic cancer	0.000146	0.000587	CbGbCtD
Vandetanib—FLT3—testis—hematologic cancer	0.000145	0.00506	CbGeAlD
Vandetanib—EGFR—lung—hematologic cancer	0.000144	0.005	CbGeAlD
Vandetanib—Bosutinib—BCR—hematologic cancer	0.000143	0.0653	CrCbGaD
Vandetanib—Bosutinib—EIF2AK1—hematologic cancer	0.000143	0.0653	CrCbGaD
Vandetanib—MKNK1—blood—hematologic cancer	0.000143	0.00497	CbGeAlD
Vandetanib—CYP3A4—Dasatinib—hematologic cancer	0.000143	0.000572	CbGbCtD
Vandetanib—STK35—testis—hematologic cancer	0.000142	0.00496	CbGeAlD
Vandetanib—FGR—blood—hematologic cancer	0.000141	0.00491	CbGeAlD
Vandetanib—RET—blood—hematologic cancer	0.000141	0.00491	CbGeAlD
Vandetanib—LCK—blood—hematologic cancer	0.000141	0.00491	CbGeAlD
Vandetanib—CYP3A4—Mitoxantrone—hematologic cancer	0.000141	0.000565	CbGbCtD
Vandetanib—FLT4—lung—hematologic cancer	0.00014	0.00487	CbGeAlD
Vandetanib—RIPK2—lung—hematologic cancer	0.000139	0.00485	CbGeAlD
Vandetanib—VEGFA—lung—hematologic cancer	0.000139	0.00483	CbGeAlD
Vandetanib—ABL2—testis—hematologic cancer	0.000139	0.00483	CbGeAlD
Vandetanib—FMO1—lung—hematologic cancer	0.000138	0.00481	CbGeAlD
Vandetanib—MKNK1—bone marrow—hematologic cancer	0.000138	0.00481	CbGeAlD
Vandetanib—PDGFRB—hematopoietic system—hematologic cancer	0.000137	0.00477	CbGeAlD
Vandetanib—LCK—bone marrow—hematologic cancer	0.000136	0.00475	CbGeAlD
Vandetanib—FGR—bone marrow—hematologic cancer	0.000136	0.00475	CbGeAlD
Vandetanib—YES1—gonad—hematologic cancer	0.000136	0.00474	CbGeAlD
Vandetanib—IRAK4—lung—hematologic cancer	0.000136	0.00473	CbGeAlD
Vandetanib—EGFR—testis—hematologic cancer	0.000135	0.00472	CbGeAlD
Vandetanib—SLK—blood—hematologic cancer	0.000135	0.0047	CbGeAlD
Vandetanib—STK10—gonad—hematologic cancer	0.000135	0.0047	CbGeAlD
Vandetanib—ERBB3—lung—hematologic cancer	0.000133	0.00464	CbGeAlD
Vandetanib—Erlotinib—ABL2—hematologic cancer	0.000133	0.0609	CrCbGaD
Vandetanib—FLT4—testis—hematologic cancer	0.000132	0.0046	CbGeAlD
Vandetanib—PLK4—lymph node—hematologic cancer	0.000132	0.00459	CbGeAlD
Vandetanib—FYN—blood—hematologic cancer	0.000131	0.00457	CbGeAlD
Vandetanib—RIPK2—testis—hematologic cancer	0.000131	0.00457	CbGeAlD
Vandetanib—VEGFA—testis—hematologic cancer	0.000131	0.00456	CbGeAlD
Vandetanib—SRC—gonad—hematologic cancer	0.000131	0.00456	CbGeAlD
Vandetanib—SLK—bone marrow—hematologic cancer	0.000131	0.00455	CbGeAlD
Vandetanib—ORM1—hematopoietic system—hematologic cancer	0.000129	0.00448	CbGeAlD
Vandetanib—MAP4K5—blood—hematologic cancer	0.000128	0.00447	CbGeAlD
Vandetanib—TEK—blood—hematologic cancer	0.000128	0.00447	CbGeAlD
Vandetanib—IRAK4—testis—hematologic cancer	0.000128	0.00447	CbGeAlD
Vandetanib—FYN—bone marrow—hematologic cancer	0.000127	0.00443	CbGeAlD
Vandetanib—ERBB3—testis—hematologic cancer	0.000126	0.00438	CbGeAlD
Vandetanib—CYP3A4—Betamethasone—hematologic cancer	0.000126	0.000503	CbGbCtD
Vandetanib—MKNK1—lung—hematologic cancer	0.000125	0.00436	CbGeAlD
Vandetanib—MAP4K5—bone marrow—hematologic cancer	0.000124	0.00433	CbGeAlD
Vandetanib—CYP3A4—Prednisolone—hematologic cancer	0.000124	0.000497	CbGbCtD
Vandetanib—FGR—lung—hematologic cancer	0.000124	0.0043	CbGeAlD
Vandetanib—LCK—lung—hematologic cancer	0.000124	0.0043	CbGeAlD
Vandetanib—AXL—lung—hematologic cancer	0.000123	0.00428	CbGeAlD
Vandetanib—EPHB6—blood—hematologic cancer	0.000123	0.00427	CbGeAlD
Vandetanib—ABL1—hematopoietic system—hematologic cancer	0.000122	0.00425	CbGeAlD
Vandetanib—Bosutinib—SYK—hematologic cancer	0.000121	0.0555	CrCbGaD
Vandetanib—BMPR1B—lymph node—hematologic cancer	0.000121	0.00423	CbGeAlD
Vandetanib—FMO3—lung—hematologic cancer	0.000119	0.00415	CbGeAlD
Vandetanib—YES1—blood—hematologic cancer	0.000119	0.00413	CbGeAlD
Vandetanib—SLK—lung—hematologic cancer	0.000118	0.00412	CbGeAlD
Vandetanib—MKNK1—testis—hematologic cancer	0.000118	0.00411	CbGeAlD
Vandetanib—STK10—blood—hematologic cancer	0.000118	0.00409	CbGeAlD
Vandetanib—CYP3A4—Prednisone—hematologic cancer	0.000117	0.000469	CbGbCtD
Vandetanib—RET—testis—hematologic cancer	0.000117	0.00406	CbGeAlD
Vandetanib—FGR—testis—hematologic cancer	0.000117	0.00406	CbGeAlD
Vandetanib—LCK—testis—hematologic cancer	0.000117	0.00406	CbGeAlD
Vandetanib—AXL—testis—hematologic cancer	0.000116	0.00404	CbGeAlD
Vandetanib—FYN—lung—hematologic cancer	0.000115	0.00401	CbGeAlD
Vandetanib—YES1—bone marrow—hematologic cancer	0.000115	0.00399	CbGeAlD
Vandetanib—SRC—blood—hematologic cancer	0.000114	0.00397	CbGeAlD
Vandetanib—STK10—bone marrow—hematologic cancer	0.000114	0.00396	CbGeAlD
Vandetanib—FMO3—testis—hematologic cancer	0.000113	0.00392	CbGeAlD
Vandetanib—MAP4K5—lung—hematologic cancer	0.000113	0.00392	CbGeAlD
Vandetanib—TEK—lung—hematologic cancer	0.000113	0.00392	CbGeAlD
Vandetanib—SLK—testis—hematologic cancer	0.000112	0.00389	CbGeAlD
Vandetanib—CYP3A4—Irinotecan—hematologic cancer	0.000111	0.000445	CbGbCtD
Vandetanib—FYN—testis—hematologic cancer	0.000109	0.00378	CbGeAlD
Vandetanib—EPHB6—lung—hematologic cancer	0.000108	0.00375	CbGeAlD
Vandetanib—MAP4K5—testis—hematologic cancer	0.000106	0.0037	CbGeAlD
Vandetanib—TEK—testis—hematologic cancer	0.000106	0.0037	CbGeAlD
Vandetanib—FLT3—lymph node—hematologic cancer	0.000105	0.00367	CbGeAlD
Vandetanib—KDR—blood—hematologic cancer	0.000105	0.00365	CbGeAlD
Vandetanib—MAP2K5—blood—hematologic cancer	0.000105	0.00365	CbGeAlD
Vandetanib—PDGFRB—gonad—hematologic cancer	0.000104	0.00363	CbGeAlD
Vandetanib—YES1—lung—hematologic cancer	0.000104	0.00362	CbGeAlD
Vandetanib—STK35—lymph node—hematologic cancer	0.000103	0.00359	CbGeAlD
Vandetanib—STK10—lung—hematologic cancer	0.000103	0.00359	CbGeAlD
Vandetanib—KDR—bone marrow—hematologic cancer	0.000102	0.00354	CbGeAlD
Vandetanib—EPHB6—testis—hematologic cancer	0.000102	0.00353	CbGeAlD
Vandetanib—ABL2—lymph node—hematologic cancer	0.000101	0.0035	CbGeAlD
Vandetanib—SRC—lung—hematologic cancer	0.0001	0.00348	CbGeAlD
Vandetanib—Bosutinib—CDK2—hematologic cancer	9.9e-05	0.0453	CrCbGaD
Vandetanib—CYP3A4—Vinblastine—hematologic cancer	9.86e-05	0.000395	CbGbCtD
Vandetanib—EGFR—lymph node—hematologic cancer	9.82e-05	0.00342	CbGeAlD
Vandetanib—YES1—testis—hematologic cancer	9.81e-05	0.00341	CbGeAlD
Vandetanib—STK10—testis—hematologic cancer	9.72e-05	0.00338	CbGeAlD
Vandetanib—CYP3A4—Vincristine—hematologic cancer	9.69e-05	0.000389	CbGbCtD
Vandetanib—FLT4—lymph node—hematologic cancer	9.57e-05	0.00333	CbGeAlD
Vandetanib—RIPK2—lymph node—hematologic cancer	9.52e-05	0.00331	CbGeAlD
Vandetanib—VEGFA—lymph node—hematologic cancer	9.49e-05	0.00331	CbGeAlD
Vandetanib—FMO1—lymph node—hematologic cancer	9.44e-05	0.00329	CbGeAlD
Vandetanib—SRC—testis—hematologic cancer	9.44e-05	0.00329	CbGeAlD
Vandetanib—IRAK4—lymph node—hematologic cancer	9.3e-05	0.00324	CbGeAlD
Vandetanib—ABL1—gonad—hematologic cancer	9.29e-05	0.00323	CbGeAlD
Vandetanib—Bosutinib—BTK—hematologic cancer	9.21e-05	0.0421	CrCbGaD
Vandetanib—Bosutinib—TXK—hematologic cancer	9.21e-05	0.0421	CrCbGaD
Vandetanib—MAP2K5—lung—hematologic cancer	9.2e-05	0.0032	CbGeAlD
Vandetanib—KDR—lung—hematologic cancer	9.2e-05	0.0032	CbGeAlD
Vandetanib—ERBB3—lymph node—hematologic cancer	9.11e-05	0.00317	CbGeAlD
Vandetanib—PDGFRB—blood—hematologic cancer	9.08e-05	0.00316	CbGeAlD
Vandetanib—CYP3A4—Etoposide—hematologic cancer	8.88e-05	0.000356	CbGbCtD
Vandetanib—PDGFRB—bone marrow—hematologic cancer	8.79e-05	0.00306	CbGeAlD
Vandetanib—KDR—testis—hematologic cancer	8.68e-05	0.00302	CbGeAlD
Vandetanib—MAP2K5—testis—hematologic cancer	8.68e-05	0.00302	CbGeAlD
Vandetanib—MKNK1—lymph node—hematologic cancer	8.56e-05	0.00298	CbGeAlD
Vandetanib—ORM1—blood—hematologic cancer	8.52e-05	0.00297	CbGeAlD
Vandetanib—LCK—lymph node—hematologic cancer	8.45e-05	0.00294	CbGeAlD
Vandetanib—RET—lymph node—hematologic cancer	8.45e-05	0.00294	CbGeAlD
Vandetanib—FGR—lymph node—hematologic cancer	8.45e-05	0.00294	CbGeAlD
Vandetanib—Afatinib—ABL1—hematologic cancer	8.42e-05	0.0385	CrCbGaD
Vandetanib—AXL—lymph node—hematologic cancer	8.42e-05	0.00293	CbGeAlD
Vandetanib—ORM1—bone marrow—hematologic cancer	8.24e-05	0.00287	CbGeAlD
Vandetanib—Bosutinib—ABL2—hematologic cancer	8.21e-05	0.0375	CrCbGaD
Vandetanib—FMO3—lymph node—hematologic cancer	8.16e-05	0.00284	CbGeAlD
Vandetanib—SLK—lymph node—hematologic cancer	8.1e-05	0.00282	CbGeAlD
Vandetanib—ABL1—blood—hematologic cancer	8.1e-05	0.00282	CbGeAlD
Vandetanib—PDGFRB—lung—hematologic cancer	7.96e-05	0.00277	CbGeAlD
Vandetanib—FYN—lymph node—hematologic cancer	7.88e-05	0.00274	CbGeAlD
Vandetanib—ABL1—bone marrow—hematologic cancer	7.83e-05	0.00273	CbGeAlD
Vandetanib—Bosutinib—LCK—hematologic cancer	7.83e-05	0.0358	CrCbGaD
Vandetanib—TEK—lymph node—hematologic cancer	7.7e-05	0.00268	CbGeAlD
Vandetanib—MAP4K5—lymph node—hematologic cancer	7.7e-05	0.00268	CbGeAlD
Vandetanib—PDGFRB—testis—hematologic cancer	7.51e-05	0.00262	CbGeAlD
Vandetanib—ORM1—lung—hematologic cancer	7.47e-05	0.0026	CbGeAlD
Vandetanib—EPHB6—lymph node—hematologic cancer	7.36e-05	0.00256	CbGeAlD
Vandetanib—CYP3A4—Dexamethasone—hematologic cancer	7.3e-05	0.000293	CbGbCtD
Vandetanib—PLK4—Topotecan—Irinotecan—hematologic cancer	7.15e-05	0.067	CbGdCrCtD
Vandetanib—YES1—lymph node—hematologic cancer	7.11e-05	0.00248	CbGeAlD
Vandetanib—PLK4—Etoposide—Teniposide—hematologic cancer	7.1e-05	0.0666	CbGdCrCtD
Vandetanib—ABL1—lung—hematologic cancer	7.1e-05	0.00247	CbGeAlD
Vandetanib—ERBB3—Podofilox—Teniposide—hematologic cancer	7.07e-05	0.0663	CbGdCrCtD
Vandetanib—STK10—lymph node—hematologic cancer	7.05e-05	0.00245	CbGeAlD
Vandetanib—Bosutinib—MAP2K1—hematologic cancer	6.98e-05	0.0319	CrCbGaD
Vandetanib—Bosutinib—FGR—hematologic cancer	6.98e-05	0.0319	CrCbGaD
Vandetanib—SRC—lymph node—hematologic cancer	6.84e-05	0.00238	CbGeAlD
Vandetanib—ABL1—testis—hematologic cancer	6.7e-05	0.00233	CbGeAlD
Vandetanib—MAP2K5—lymph node—hematologic cancer	6.29e-05	0.00219	CbGeAlD
Vandetanib—KDR—lymph node—hematologic cancer	6.29e-05	0.00219	CbGeAlD
Vandetanib—ALB—testis—hematologic cancer	6.18e-05	0.00215	CbGeAlD
Vandetanib—ABCC1—blood—hematologic cancer	6.17e-05	0.00215	CbGeAlD
Vandetanib—CYP3A4—Doxorubicin—hematologic cancer	6.06e-05	0.000243	CbGbCtD
Vandetanib—ABL1—Topotecan—Irinotecan—hematologic cancer	6.01e-05	0.0564	CbGdCrCtD
Vandetanib—Erlotinib—ABL1—hematologic cancer	5.95e-05	0.0272	CrCbGaD
Vandetanib—PDGFRB—lymph node—hematologic cancer	5.45e-05	0.0019	CbGeAlD
Vandetanib—ABCC1—lung—hematologic cancer	5.41e-05	0.00188	CbGeAlD
Vandetanib—CYP3A4—hematopoietic system—hematologic cancer	5.37e-05	0.00187	CbGeAlD
Vandetanib—ORM1—lymph node—hematologic cancer	5.11e-05	0.00178	CbGeAlD
Vandetanib—ABCG2—blood—hematologic cancer	5.11e-05	0.00178	CbGeAlD
Vandetanib—ABCC1—testis—hematologic cancer	5.1e-05	0.00178	CbGeAlD
Vandetanib—Bosutinib—ALK—hematologic cancer	4.97e-05	0.0227	CrCbGaD
Vandetanib—ABCG2—bone marrow—hematologic cancer	4.94e-05	0.00172	CbGeAlD
Vandetanib—ABL1—lymph node—hematologic cancer	4.85e-05	0.00169	CbGeAlD
Vandetanib—PLK4—Epirubicin—Daunorubicin—hematologic cancer	4.83e-05	0.0453	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Daunorubicin—hematologic cancer	4.83e-05	0.0453	CbGdCrCtD
Vandetanib—PLK4—Doxorubicin—Daunorubicin—hematologic cancer	4.83e-05	0.0453	CbGdCrCtD
Vandetanib—Bosutinib—CSF1R—hematologic cancer	4.71e-05	0.0215	CrCbGaD
Vandetanib—Erlotinib—UGT1A1—hematologic cancer	4.7e-05	0.0215	CrCbGaD
Vandetanib—ALB—lymph node—hematologic cancer	4.48e-05	0.00156	CbGeAlD
Vandetanib—ABCG2—lung—hematologic cancer	4.48e-05	0.00156	CbGeAlD
Vandetanib—ABCG2—testis—hematologic cancer	4.22e-05	0.00147	CbGeAlD
Vandetanib—ERBB3—Podofilox—Etoposide—hematologic cancer	4.2e-05	0.0394	CbGdCrCtD
Vandetanib—Bosutinib—PDGFRB—hematologic cancer	4.11e-05	0.0188	CrCbGaD
Vandetanib—PLK4—Menadione—Thalidomide—hematologic cancer	4.11e-05	0.0385	CbGdCrCtD
Vandetanib—ABL1—Epirubicin—Daunorubicin—hematologic cancer	4.06e-05	0.0381	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Daunorubicin—hematologic cancer	4.06e-05	0.0381	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Daunorubicin—hematologic cancer	4.06e-05	0.0381	CbGdCrCtD
Vandetanib—Afatinib—ABCG2—hematologic cancer	3.74e-05	0.0171	CrCbGaD
Vandetanib—ABCC1—lymph node—hematologic cancer	3.7e-05	0.00129	CbGeAlD
Vandetanib—Bosutinib—ABL1—hematologic cancer	3.67e-05	0.0168	CrCbGaD
Vandetanib—PLK4—Doxorubicin—Idarubicin—hematologic cancer	3.66e-05	0.0343	CbGdCrCtD
Vandetanib—PLK4—Epirubicin—Idarubicin—hematologic cancer	3.66e-05	0.0343	CbGdCrCtD
Vandetanib—ERBB3—Vinblastine—Vinorelbine—hematologic cancer	3.62e-05	0.0339	CbGdCrCtD
Vandetanib—CYP3A4—blood—hematologic cancer	3.56e-05	0.00124	CbGeAlD
Vandetanib—Bosutinib—SRC—hematologic cancer	3.32e-05	0.0152	CrCbGaD
Vandetanib—PLK4—Teniposide—Etoposide—hematologic cancer	3.22e-05	0.0302	CbGdCrCtD
Vandetanib—ABL1—Epirubicin—Idarubicin—hematologic cancer	3.08e-05	0.0288	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Idarubicin—hematologic cancer	3.08e-05	0.0288	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Idarubicin—hematologic cancer	3.08e-05	0.0288	CbGdCrCtD
Vandetanib—ABCG2—lymph node—hematologic cancer	3.06e-05	0.00107	CbGeAlD
Vandetanib—ERBB3—Vinblastine—Vincristine—hematologic cancer	2.89e-05	0.0271	CbGdCrCtD
Vandetanib—Erlotinib—ABCG2—hematologic cancer	2.64e-05	0.0121	CrCbGaD
Vandetanib—PLK4—Doxorubicin—Epirubicin—hematologic cancer	1.68e-05	0.0158	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Epirubicin—hematologic cancer	1.68e-05	0.0158	CbGdCrCtD
Vandetanib—Gefitinib—ABCG2—hematologic cancer	1.65e-05	0.00756	CrCbGaD
Vandetanib—Afatinib—ABCB1—hematologic cancer	1.56e-05	0.00712	CrCbGaD
Vandetanib—PLK4—Idarubicin—Doxorubicin—hematologic cancer	1.55e-05	0.0146	CbGdCrCtD
Vandetanib—PLK4—Epirubicin—Doxorubicin—hematologic cancer	1.55e-05	0.0146	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Epirubicin—hematologic cancer	1.41e-05	0.0132	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Epirubicin—hematologic cancer	1.41e-05	0.0132	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—hematologic cancer	1.41e-05	0.0132	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—hematologic cancer	1.31e-05	0.0123	CbGdCrCtD
Vandetanib—ABL1—Epirubicin—Doxorubicin—hematologic cancer	1.31e-05	0.0123	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—hematologic cancer	1.31e-05	0.0123	CbGdCrCtD
Vandetanib—Erlotinib—ALB—hematologic cancer	1.15e-05	0.00527	CrCbGaD
Vandetanib—Erlotinib—ABCB1—hematologic cancer	1.1e-05	0.00503	CrCbGaD
Vandetanib—Gefitinib—ALB—hematologic cancer	7.22e-06	0.0033	CrCbGaD
Vandetanib—Gefitinib—ABCB1—hematologic cancer	6.89e-06	0.00315	CrCbGaD
Vandetanib—Bosutinib—ABCB1—hematologic cancer	6.78e-06	0.0031	CrCbGaD
Vandetanib—Convulsion—Prednisone—hematologic cancer	5.03e-06	7.76e-05	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—hematologic cancer	5.03e-06	7.75e-05	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—hematologic cancer	5.02e-06	7.75e-05	CcSEcCtD
Vandetanib—Hypertension—Prednisone—hematologic cancer	5.01e-06	7.73e-05	CcSEcCtD
Vandetanib—Rash—Mitoxantrone—hematologic cancer	5.01e-06	7.73e-05	CcSEcCtD
Vandetanib—Rash—Irinotecan—hematologic cancer	5.01e-06	7.73e-05	CcSEcCtD
Vandetanib—Dermatitis—Irinotecan—hematologic cancer	5.01e-06	7.72e-05	CcSEcCtD
Vandetanib—Dermatitis—Mitoxantrone—hematologic cancer	5.01e-06	7.72e-05	CcSEcCtD
Vandetanib—Headache—Mitoxantrone—hematologic cancer	4.98e-06	7.68e-05	CcSEcCtD
Vandetanib—Headache—Irinotecan—hematologic cancer	4.98e-06	7.68e-05	CcSEcCtD
Vandetanib—Nausea—Ifosfamide—hematologic cancer	4.97e-06	7.67e-05	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	4.96e-06	7.65e-05	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Betamethasone—hematologic cancer	4.96e-06	7.65e-05	CcSEcCtD
Vandetanib—Arthralgia—Prednisone—hematologic cancer	4.94e-06	7.62e-05	CcSEcCtD
Vandetanib—Diarrhoea—Cisplatin—hematologic cancer	4.94e-06	7.62e-05	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—hematologic cancer	4.93e-06	7.61e-05	CcSEcCtD
Vandetanib—Anxiety—Prednisone—hematologic cancer	4.93e-06	7.6e-05	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—hematologic cancer	4.93e-06	7.6e-05	CcSEcCtD
Vandetanib—Vomiting—Gemcitabine—hematologic cancer	4.92e-06	7.59e-05	CcSEcCtD
Vandetanib—Insomnia—Dexamethasone—hematologic cancer	4.92e-06	7.59e-05	CcSEcCtD
Vandetanib—Insomnia—Betamethasone—hematologic cancer	4.92e-06	7.59e-05	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—hematologic cancer	4.91e-06	7.58e-05	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	4.91e-06	7.57e-05	CcSEcCtD
Vandetanib—Paraesthesia—Betamethasone—hematologic cancer	4.89e-06	7.54e-05	CcSEcCtD
Vandetanib—Paraesthesia—Dexamethasone—hematologic cancer	4.89e-06	7.54e-05	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—hematologic cancer	4.88e-06	7.53e-05	CcSEcCtD
Vandetanib—Rash—Gemcitabine—hematologic cancer	4.88e-06	7.53e-05	CcSEcCtD
Vandetanib—Dermatitis—Gemcitabine—hematologic cancer	4.88e-06	7.52e-05	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—hematologic cancer	4.88e-06	7.52e-05	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—hematologic cancer	4.85e-06	7.48e-05	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—hematologic cancer	4.85e-06	7.48e-05	CcSEcCtD
Vandetanib—Headache—Gemcitabine—hematologic cancer	4.85e-06	7.48e-05	CcSEcCtD
Vandetanib—Nausea—Vincristine—hematologic cancer	4.85e-06	7.48e-05	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—hematologic cancer	4.84e-06	7.47e-05	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—hematologic cancer	4.83e-06	7.44e-05	CcSEcCtD
Vandetanib—Dyspepsia—Betamethasone—hematologic cancer	4.79e-06	7.39e-05	CcSEcCtD
Vandetanib—Dyspepsia—Dexamethasone—hematologic cancer	4.79e-06	7.39e-05	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—hematologic cancer	4.77e-06	7.35e-05	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—hematologic cancer	4.75e-06	7.33e-05	CcSEcCtD
Vandetanib—Asthenia—Etoposide—hematologic cancer	4.74e-06	7.32e-05	CcSEcCtD
Vandetanib—Body temperature increased—Triamcinolone—hematologic cancer	4.74e-06	7.31e-05	CcSEcCtD
Vandetanib—Oedema—Prednisone—hematologic cancer	4.74e-06	7.31e-05	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—hematologic cancer	4.73e-06	7.3e-05	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—hematologic cancer	4.73e-06	7.3e-05	CcSEcCtD
Vandetanib—Decreased appetite—Betamethasone—hematologic cancer	4.73e-06	7.3e-05	CcSEcCtD
Vandetanib—Decreased appetite—Dexamethasone—hematologic cancer	4.73e-06	7.3e-05	CcSEcCtD
Vandetanib—Nausea—Irinotecan—hematologic cancer	4.72e-06	7.28e-05	CcSEcCtD
Vandetanib—Nausea—Mitoxantrone—hematologic cancer	4.72e-06	7.28e-05	CcSEcCtD
Vandetanib—Infection—Prednisone—hematologic cancer	4.71e-06	7.26e-05	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—hematologic cancer	4.7e-06	7.25e-05	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Betamethasone—hematologic cancer	4.7e-06	7.25e-05	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Dexamethasone—hematologic cancer	4.7e-06	7.25e-05	CcSEcCtD
Vandetanib—Fatigue—Betamethasone—hematologic cancer	4.69e-06	7.24e-05	CcSEcCtD
Vandetanib—Fatigue—Dexamethasone—hematologic cancer	4.69e-06	7.24e-05	CcSEcCtD
Vandetanib—Pruritus—Etoposide—hematologic cancer	4.68e-06	7.21e-05	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—hematologic cancer	4.66e-06	7.19e-05	CcSEcCtD
Vandetanib—Pain—Dexamethasone—hematologic cancer	4.65e-06	7.18e-05	CcSEcCtD
Vandetanib—Pain—Betamethasone—hematologic cancer	4.65e-06	7.18e-05	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—hematologic cancer	4.65e-06	7.17e-05	CcSEcCtD
Vandetanib—Nervous system disorder—Prednisone—hematologic cancer	4.65e-06	7.17e-05	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—hematologic cancer	4.61e-06	7.11e-05	CcSEcCtD
Vandetanib—Skin disorder—Prednisone—hematologic cancer	4.6e-06	7.1e-05	CcSEcCtD
Vandetanib—Nausea—Gemcitabine—hematologic cancer	4.6e-06	7.09e-05	CcSEcCtD
Vandetanib—Vomiting—Cisplatin—hematologic cancer	4.59e-06	7.08e-05	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—hematologic cancer	4.57e-06	7.05e-05	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—hematologic cancer	4.57e-06	7.05e-05	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—hematologic cancer	4.56e-06	7.04e-05	CcSEcCtD
Vandetanib—Rash—Cisplatin—hematologic cancer	4.55e-06	7.02e-05	CcSEcCtD
Vandetanib—Dermatitis—Cisplatin—hematologic cancer	4.55e-06	7.01e-05	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—hematologic cancer	4.54e-06	7e-05	CcSEcCtD
Vandetanib—Diarrhoea—Etoposide—hematologic cancer	4.52e-06	6.98e-05	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—hematologic cancer	4.51e-06	6.96e-05	CcSEcCtD
Vandetanib—VEGFA—Dexamethasone—Betamethasone—hematologic cancer	4.49e-06	0.00421	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Dexamethasone—hematologic cancer	4.49e-06	0.00421	CbGdCrCtD
Vandetanib—Cardiac disorder—Doxorubicin—hematologic cancer	4.48e-06	6.91e-05	CcSEcCtD
Vandetanib—Gastrointestinal pain—Betamethasone—hematologic cancer	4.45e-06	6.86e-05	CcSEcCtD
Vandetanib—Gastrointestinal pain—Dexamethasone—hematologic cancer	4.45e-06	6.86e-05	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—hematologic cancer	4.45e-06	6.86e-05	CcSEcCtD
Vandetanib—VEGFA—Betamethasone—Triamcinolone—hematologic cancer	4.39e-06	0.00412	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Triamcinolone—hematologic cancer	4.39e-06	0.00412	CbGdCrCtD
Vandetanib—Angiopathy—Doxorubicin—hematologic cancer	4.38e-06	6.75e-05	CcSEcCtD
Vandetanib—Dizziness—Etoposide—hematologic cancer	4.37e-06	6.74e-05	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—hematologic cancer	4.37e-06	6.73e-05	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—hematologic cancer	4.35e-06	6.71e-05	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Prednisone—hematologic cancer	4.32e-06	6.66e-05	CcSEcCtD
Vandetanib—Dizziness—Prednisolone—hematologic cancer	4.31e-06	6.65e-05	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—hematologic cancer	4.31e-06	6.65e-05	CcSEcCtD
Vandetanib—Asthenia—Triamcinolone—hematologic cancer	4.3e-06	6.64e-05	CcSEcCtD
Vandetanib—Body temperature increased—Betamethasone—hematologic cancer	4.3e-06	6.63e-05	CcSEcCtD
Vandetanib—Abdominal pain—Dexamethasone—hematologic cancer	4.3e-06	6.63e-05	CcSEcCtD
Vandetanib—Body temperature increased—Dexamethasone—hematologic cancer	4.3e-06	6.63e-05	CcSEcCtD
Vandetanib—Abdominal pain—Betamethasone—hematologic cancer	4.3e-06	6.63e-05	CcSEcCtD
Vandetanib—Nausea—Cisplatin—hematologic cancer	4.29e-06	6.61e-05	CcSEcCtD
Vandetanib—Insomnia—Prednisone—hematologic cancer	4.29e-06	6.61e-05	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—hematologic cancer	4.28e-06	6.6e-05	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—hematologic cancer	4.27e-06	6.58e-05	CcSEcCtD
Vandetanib—Paraesthesia—Prednisone—hematologic cancer	4.26e-06	6.56e-05	CcSEcCtD
Vandetanib—Pruritus—Triamcinolone—hematologic cancer	4.24e-06	6.54e-05	CcSEcCtD
Vandetanib—Cough—Methotrexate—hematologic cancer	4.23e-06	6.53e-05	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—hematologic cancer	4.23e-06	6.52e-05	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—hematologic cancer	4.2e-06	6.48e-05	CcSEcCtD
Vandetanib—Vomiting—Etoposide—hematologic cancer	4.2e-06	6.48e-05	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—hematologic cancer	4.2e-06	6.48e-05	CcSEcCtD
Vandetanib—Dyspepsia—Prednisone—hematologic cancer	4.17e-06	6.43e-05	CcSEcCtD
Vandetanib—Rash—Etoposide—hematologic cancer	4.17e-06	6.43e-05	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—hematologic cancer	4.17e-06	6.42e-05	CcSEcCtD
Vandetanib—VEGFA—Betamethasone—Prednisone—hematologic cancer	4.16e-06	0.00391	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Prednisone—hematologic cancer	4.16e-06	0.00391	CbGdCrCtD
Vandetanib—Headache—Etoposide—hematologic cancer	4.14e-06	6.39e-05	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—hematologic cancer	4.13e-06	6.37e-05	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—hematologic cancer	4.13e-06	6.37e-05	CcSEcCtD
Vandetanib—Decreased appetite—Prednisone—hematologic cancer	4.12e-06	6.35e-05	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—hematologic cancer	4.12e-06	6.35e-05	CcSEcCtD
Vandetanib—Rash—Prednisolone—hematologic cancer	4.11e-06	6.34e-05	CcSEcCtD
Vandetanib—Dermatitis—Prednisolone—hematologic cancer	4.11e-06	6.34e-05	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.1e-06	6.33e-05	CcSEcCtD
Vandetanib—Fatigue—Prednisone—hematologic cancer	4.09e-06	6.3e-05	CcSEcCtD
Vandetanib—Headache—Prednisolone—hematologic cancer	4.09e-06	6.3e-05	CcSEcCtD
Vandetanib—VEGFA—Betamethasone—Prednisolone—hematologic cancer	4.07e-06	0.00381	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Prednisolone—hematologic cancer	4.07e-06	0.00381	CbGdCrCtD
Vandetanib—Constipation—Prednisone—hematologic cancer	4.05e-06	6.25e-05	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—hematologic cancer	4.04e-06	6.23e-05	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—hematologic cancer	3.99e-06	6.16e-05	CcSEcCtD
Vandetanib—Dizziness—Triamcinolone—hematologic cancer	3.97e-06	6.12e-05	CcSEcCtD
Vandetanib—Cough—Epirubicin—hematologic cancer	3.96e-06	6.11e-05	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—hematologic cancer	3.96e-06	6.11e-05	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—hematologic cancer	3.94e-06	6.07e-05	CcSEcCtD
Vandetanib—Infection—Methotrexate—hematologic cancer	3.93e-06	6.07e-05	CcSEcCtD
Vandetanib—Nausea—Etoposide—hematologic cancer	3.93e-06	6.06e-05	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—hematologic cancer	3.92e-06	6.05e-05	CcSEcCtD
Vandetanib—Asthenia—Dexamethasone—hematologic cancer	3.9e-06	6.02e-05	CcSEcCtD
Vandetanib—Asthenia—Betamethasone—hematologic cancer	3.9e-06	6.02e-05	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—hematologic cancer	3.88e-06	5.99e-05	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—hematologic cancer	3.88e-06	5.98e-05	CcSEcCtD
Vandetanib—Gastrointestinal pain—Prednisone—hematologic cancer	3.88e-06	5.98e-05	CcSEcCtD
Vandetanib—Nausea—Prednisolone—hematologic cancer	3.87e-06	5.97e-05	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—hematologic cancer	3.87e-06	5.96e-05	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—hematologic cancer	3.87e-06	5.96e-05	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—hematologic cancer	3.85e-06	5.94e-05	CcSEcCtD
Vandetanib—Pruritus—Dexamethasone—hematologic cancer	3.85e-06	5.94e-05	CcSEcCtD
Vandetanib—Pruritus—Betamethasone—hematologic cancer	3.85e-06	5.94e-05	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—hematologic cancer	3.85e-06	5.93e-05	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.84e-06	5.92e-05	CcSEcCtD
Vandetanib—Vomiting—Triamcinolone—hematologic cancer	3.81e-06	5.88e-05	CcSEcCtD
Vandetanib—Rash—Triamcinolone—hematologic cancer	3.78e-06	5.83e-05	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—hematologic cancer	3.78e-06	5.83e-05	CcSEcCtD
Vandetanib—Dermatitis—Triamcinolone—hematologic cancer	3.78e-06	5.83e-05	CcSEcCtD
Vandetanib—Headache—Triamcinolone—hematologic cancer	3.76e-06	5.79e-05	CcSEcCtD
Vandetanib—Abdominal pain—Prednisone—hematologic cancer	3.75e-06	5.78e-05	CcSEcCtD
Vandetanib—Body temperature increased—Prednisone—hematologic cancer	3.75e-06	5.78e-05	CcSEcCtD
Vandetanib—Diarrhoea—Betamethasone—hematologic cancer	3.72e-06	5.74e-05	CcSEcCtD
Vandetanib—Diarrhoea—Dexamethasone—hematologic cancer	3.72e-06	5.74e-05	CcSEcCtD
Vandetanib—Oedema—Epirubicin—hematologic cancer	3.71e-06	5.72e-05	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—hematologic cancer	3.69e-06	5.7e-05	CcSEcCtD
Vandetanib—Infection—Epirubicin—hematologic cancer	3.68e-06	5.68e-05	CcSEcCtD
Vandetanib—Cough—Doxorubicin—hematologic cancer	3.67e-06	5.66e-05	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—hematologic cancer	3.64e-06	5.62e-05	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—hematologic cancer	3.63e-06	5.61e-05	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—hematologic cancer	3.63e-06	5.6e-05	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—hematologic cancer	3.63e-06	5.6e-05	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.61e-06	5.57e-05	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—hematologic cancer	3.6e-06	5.55e-05	CcSEcCtD
Vandetanib—Dizziness—Dexamethasone—hematologic cancer	3.6e-06	5.55e-05	CcSEcCtD
Vandetanib—Dizziness—Betamethasone—hematologic cancer	3.6e-06	5.55e-05	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—hematologic cancer	3.58e-06	5.52e-05	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—hematologic cancer	3.58e-06	5.52e-05	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—hematologic cancer	3.58e-06	5.52e-05	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—hematologic cancer	3.57e-06	5.5e-05	CcSEcCtD
Vandetanib—Nausea—Triamcinolone—hematologic cancer	3.56e-06	5.49e-05	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—hematologic cancer	3.56e-06	5.48e-05	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	3.55e-06	5.48e-05	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—hematologic cancer	3.53e-06	5.45e-05	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—hematologic cancer	3.5e-06	5.4e-05	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—hematologic cancer	3.49e-06	5.38e-05	CcSEcCtD
Vandetanib—Vomiting—Dexamethasone—hematologic cancer	3.46e-06	5.34e-05	CcSEcCtD
Vandetanib—Vomiting—Betamethasone—hematologic cancer	3.46e-06	5.34e-05	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—hematologic cancer	3.44e-06	5.31e-05	CcSEcCtD
Vandetanib—Rash—Dexamethasone—hematologic cancer	3.43e-06	5.29e-05	CcSEcCtD
Vandetanib—Rash—Betamethasone—hematologic cancer	3.43e-06	5.29e-05	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—hematologic cancer	3.43e-06	5.29e-05	CcSEcCtD
Vandetanib—Dermatitis—Betamethasone—hematologic cancer	3.43e-06	5.29e-05	CcSEcCtD
Vandetanib—Dermatitis—Dexamethasone—hematologic cancer	3.43e-06	5.29e-05	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.42e-06	5.27e-05	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—hematologic cancer	3.41e-06	5.27e-05	CcSEcCtD
Vandetanib—Headache—Dexamethasone—hematologic cancer	3.41e-06	5.26e-05	CcSEcCtD
Vandetanib—Headache—Betamethasone—hematologic cancer	3.41e-06	5.26e-05	CcSEcCtD
Vandetanib—Infection—Doxorubicin—hematologic cancer	3.41e-06	5.25e-05	CcSEcCtD
Vandetanib—Asthenia—Prednisone—hematologic cancer	3.4e-06	5.24e-05	CcSEcCtD
Vandetanib—Pain—Methotrexate—hematologic cancer	3.39e-06	5.22e-05	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—hematologic cancer	3.38e-06	5.21e-05	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—hematologic cancer	3.36e-06	5.19e-05	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—hematologic cancer	3.36e-06	5.18e-05	CcSEcCtD
Vandetanib—Pruritus—Prednisone—hematologic cancer	3.35e-06	5.17e-05	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—hematologic cancer	3.35e-06	5.17e-05	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—hematologic cancer	3.33e-06	5.14e-05	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—hematologic cancer	3.33e-06	5.13e-05	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—hematologic cancer	3.3e-06	5.1e-05	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—hematologic cancer	3.26e-06	5.03e-05	CcSEcCtD
Vandetanib—Diarrhoea—Prednisone—hematologic cancer	3.24e-06	5e-05	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—hematologic cancer	3.24e-06	4.99e-05	CcSEcCtD
Vandetanib—Nausea—Betamethasone—hematologic cancer	3.23e-06	4.99e-05	CcSEcCtD
Vandetanib—Nausea—Dexamethasone—hematologic cancer	3.23e-06	4.99e-05	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—hematologic cancer	3.22e-06	4.97e-05	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.2e-06	4.94e-05	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—hematologic cancer	3.2e-06	4.93e-05	CcSEcCtD
Vandetanib—Pain—Epirubicin—hematologic cancer	3.17e-06	4.89e-05	CcSEcCtD
Vandetanib—Constipation—Epirubicin—hematologic cancer	3.17e-06	4.89e-05	CcSEcCtD
Vandetanib—Dizziness—Prednisone—hematologic cancer	3.13e-06	4.83e-05	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—hematologic cancer	3.13e-06	4.83e-05	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—hematologic cancer	3.13e-06	4.83e-05	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.12e-06	4.82e-05	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—hematologic cancer	3.1e-06	4.78e-05	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—hematologic cancer	3.08e-06	4.75e-05	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—hematologic cancer	3.06e-06	4.72e-05	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—hematologic cancer	3.03e-06	4.67e-05	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—hematologic cancer	3.02e-06	4.66e-05	CcSEcCtD
Vandetanib—Vomiting—Prednisone—hematologic cancer	3.01e-06	4.65e-05	CcSEcCtD
Vandetanib—Rash—Prednisone—hematologic cancer	2.99e-06	4.61e-05	CcSEcCtD
Vandetanib—Dermatitis—Prednisone—hematologic cancer	2.99e-06	4.6e-05	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—hematologic cancer	2.98e-06	4.6e-05	CcSEcCtD
Vandetanib—Headache—Prednisone—hematologic cancer	2.97e-06	4.58e-05	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.96e-06	4.57e-05	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—hematologic cancer	2.96e-06	4.56e-05	CcSEcCtD
Vandetanib—Pain—Doxorubicin—hematologic cancer	2.93e-06	4.52e-05	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—hematologic cancer	2.93e-06	4.52e-05	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—hematologic cancer	2.93e-06	4.52e-05	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—hematologic cancer	2.93e-06	4.52e-05	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—hematologic cancer	2.84e-06	4.38e-05	CcSEcCtD
Vandetanib—Nausea—Prednisone—hematologic cancer	2.82e-06	4.34e-05	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.8e-06	4.33e-05	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—hematologic cancer	2.8e-06	4.32e-05	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—hematologic cancer	2.71e-06	4.18e-05	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—hematologic cancer	2.71e-06	4.18e-05	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—hematologic cancer	2.71e-06	4.18e-05	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—hematologic cancer	2.66e-06	4.1e-05	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—hematologic cancer	2.62e-06	4.04e-05	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—hematologic cancer	2.62e-06	4.04e-05	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—hematologic cancer	2.54e-06	3.91e-05	CcSEcCtD
Vandetanib—Vomiting—Methotrexate—hematologic cancer	2.52e-06	3.88e-05	CcSEcCtD
Vandetanib—Rash—Methotrexate—hematologic cancer	2.5e-06	3.85e-05	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—hematologic cancer	2.5e-06	3.85e-05	CcSEcCtD
Vandetanib—Headache—Methotrexate—hematologic cancer	2.48e-06	3.83e-05	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—hematologic cancer	2.46e-06	3.79e-05	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—hematologic cancer	2.45e-06	3.78e-05	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—hematologic cancer	2.43e-06	3.74e-05	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—hematologic cancer	2.36e-06	3.63e-05	CcSEcCtD
Vandetanib—Nausea—Methotrexate—hematologic cancer	2.35e-06	3.63e-05	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—hematologic cancer	2.35e-06	3.62e-05	CcSEcCtD
Vandetanib—Rash—Epirubicin—hematologic cancer	2.34e-06	3.6e-05	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—hematologic cancer	2.33e-06	3.6e-05	CcSEcCtD
Vandetanib—Headache—Epirubicin—hematologic cancer	2.32e-06	3.58e-05	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—hematologic cancer	2.27e-06	3.5e-05	CcSEcCtD
Vandetanib—Nausea—Epirubicin—hematologic cancer	2.2e-06	3.4e-05	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—hematologic cancer	2.18e-06	3.36e-05	CcSEcCtD
Vandetanib—Rash—Doxorubicin—hematologic cancer	2.16e-06	3.33e-05	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—hematologic cancer	2.16e-06	3.33e-05	CcSEcCtD
Vandetanib—Headache—Doxorubicin—hematologic cancer	2.15e-06	3.31e-05	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—hematologic cancer	2.04e-06	3.14e-05	CcSEcCtD
Vandetanib—SRC—Immune System—STAT3—hematologic cancer	1.25e-07	1.99e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1A—hematologic cancer	1.24e-07	1.99e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—hematologic cancer	1.24e-07	1.99e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MAPK3—hematologic cancer	1.24e-07	1.98e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTEN—hematologic cancer	1.24e-07	1.98e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK8—hematologic cancer	1.24e-07	1.98e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—hematologic cancer	1.24e-07	1.98e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JAK2—hematologic cancer	1.24e-07	1.98e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—hematologic cancer	1.24e-07	1.98e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—hematologic cancer	1.23e-07	1.97e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—hematologic cancer	1.23e-07	1.97e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—hematologic cancer	1.23e-07	1.96e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—hematologic cancer	1.23e-07	1.96e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EP300—hematologic cancer	1.23e-07	1.96e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SDC1—hematologic cancer	1.23e-07	1.96e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—hematologic cancer	1.23e-07	1.96e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1A—hematologic cancer	1.23e-07	1.96e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—hematologic cancer	1.22e-07	1.96e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTEN—hematologic cancer	1.22e-07	1.95e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MTOR—hematologic cancer	1.22e-07	1.95e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CB—hematologic cancer	1.22e-07	1.95e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—hematologic cancer	1.22e-07	1.94e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK8—hematologic cancer	1.21e-07	1.94e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MDM2—hematologic cancer	1.21e-07	1.93e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EP300—hematologic cancer	1.21e-07	1.93e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—hematologic cancer	1.21e-07	1.93e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—hematologic cancer	1.21e-07	1.93e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—hematologic cancer	1.2e-07	1.92e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAP2K1—hematologic cancer	1.2e-07	1.92e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—hematologic cancer	1.2e-07	1.92e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—hematologic cancer	1.2e-07	1.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CD—hematologic cancer	1.2e-07	1.91e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK8—hematologic cancer	1.2e-07	1.91e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—hematologic cancer	1.19e-07	1.91e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK3—hematologic cancer	1.19e-07	1.9e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—hematologic cancer	1.18e-07	1.89e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EP300—hematologic cancer	1.18e-07	1.89e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—hematologic cancer	1.18e-07	1.89e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—hematologic cancer	1.18e-07	1.89e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTEN—hematologic cancer	1.18e-07	1.88e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MTOR—hematologic cancer	1.18e-07	1.88e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CB—hematologic cancer	1.18e-07	1.88e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—hematologic cancer	1.18e-07	1.88e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SRC—hematologic cancer	1.18e-07	1.88e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—hematologic cancer	1.17e-07	1.88e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—hematologic cancer	1.17e-07	1.87e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—hematologic cancer	1.17e-07	1.86e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EP300—hematologic cancer	1.17e-07	1.86e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—hematologic cancer	1.16e-07	1.85e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.15e-07	1.84e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—hematologic cancer	1.15e-07	1.84e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SRC—hematologic cancer	1.15e-07	1.84e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—hematologic cancer	1.15e-07	1.84e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—hematologic cancer	1.15e-07	1.83e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1B—hematologic cancer	1.15e-07	1.83e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—hematologic cancer	1.15e-07	1.83e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGF2—hematologic cancer	1.15e-07	1.83e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—hematologic cancer	1.14e-07	1.82e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—hematologic cancer	1.14e-07	1.82e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—hematologic cancer	1.13e-07	1.81e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—hematologic cancer	1.13e-07	1.81e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SRC—hematologic cancer	1.13e-07	1.81e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—hematologic cancer	1.13e-07	1.81e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—hematologic cancer	1.13e-07	1.81e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—hematologic cancer	1.13e-07	1.81e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3R1—hematologic cancer	1.13e-07	1.8e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—hematologic cancer	1.13e-07	1.8e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—hematologic cancer	1.13e-07	1.8e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—EP300—hematologic cancer	1.12e-07	1.8e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—hematologic cancer	1.12e-07	1.8e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—hematologic cancer	1.12e-07	1.79e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—hematologic cancer	1.12e-07	1.79e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—hematologic cancer	1.12e-07	1.78e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—hematologic cancer	1.12e-07	1.78e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—hematologic cancer	1.11e-07	1.77e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—hematologic cancer	1.11e-07	1.77e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—hematologic cancer	1.11e-07	1.77e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—hematologic cancer	1.11e-07	1.77e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—hematologic cancer	1.11e-07	1.77e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1B—hematologic cancer	1.11e-07	1.77e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—hematologic cancer	1.1e-07	1.76e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—hematologic cancer	1.1e-07	1.76e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MAPK3—hematologic cancer	1.1e-07	1.76e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—hematologic cancer	1.1e-07	1.76e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JAK2—hematologic cancer	1.1e-07	1.75e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—hematologic cancer	1.09e-07	1.75e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—hematologic cancer	1.09e-07	1.75e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—hematologic cancer	1.09e-07	1.75e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JUN—hematologic cancer	1.09e-07	1.74e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—hematologic cancer	1.09e-07	1.74e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—hematologic cancer	1.09e-07	1.74e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—hematologic cancer	1.09e-07	1.74e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—hematologic cancer	1.09e-07	1.74e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK3—hematologic cancer	1.08e-07	1.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—hematologic cancer	1.08e-07	1.73e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—hematologic cancer	1.08e-07	1.73e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—hematologic cancer	1.08e-07	1.72e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MDM2—hematologic cancer	1.07e-07	1.71e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—hematologic cancer	1.07e-07	1.71e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—hematologic cancer	1.07e-07	1.71e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—hematologic cancer	1.07e-07	1.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—hematologic cancer	1.07e-07	1.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—hematologic cancer	1.06e-07	1.7e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK3—hematologic cancer	1.06e-07	1.69e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1A—hematologic cancer	1.06e-07	1.69e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTEN—hematologic cancer	1.06e-07	1.69e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—hematologic cancer	1.05e-07	1.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—hematologic cancer	1.05e-07	1.68e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JUN—hematologic cancer	1.05e-07	1.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—hematologic cancer	1.05e-07	1.68e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK3—hematologic cancer	1.04e-07	1.67e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—hematologic cancer	1.04e-07	1.67e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—hematologic cancer	1.04e-07	1.67e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MTOR—hematologic cancer	1.04e-07	1.67e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CB—hematologic cancer	1.04e-07	1.67e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NQO1—hematologic cancer	1.04e-07	1.67e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CD44—hematologic cancer	1.04e-07	1.67e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—hematologic cancer	1.04e-07	1.66e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—hematologic cancer	1.03e-07	1.65e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK8—hematologic cancer	1.03e-07	1.65e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—hematologic cancer	1.03e-07	1.65e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—hematologic cancer	1.03e-07	1.65e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—hematologic cancer	1.03e-07	1.64e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—hematologic cancer	1.03e-07	1.64e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—hematologic cancer	1.03e-07	1.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—hematologic cancer	1.02e-07	1.63e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1A—hematologic cancer	1.02e-07	1.63e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CREBBP—hematologic cancer	1.02e-07	1.63e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTEN—hematologic cancer	1.02e-07	1.63e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—hematologic cancer	1.02e-07	1.62e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—hematologic cancer	1.01e-07	1.62e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—EP300—hematologic cancer	1.01e-07	1.61e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—hematologic cancer	1.01e-07	1.61e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—hematologic cancer	9.99e-08	1.6e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK8—hematologic cancer	9.96e-08	1.59e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—hematologic cancer	9.93e-08	1.59e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—hematologic cancer	9.88e-08	1.58e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYCS—hematologic cancer	9.86e-08	1.58e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—hematologic cancer	9.84e-08	1.57e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—hematologic cancer	9.83e-08	1.57e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—hematologic cancer	9.83e-08	1.57e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	9.8e-08	1.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SRC—hematologic cancer	9.79e-08	1.56e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1B—hematologic cancer	9.78e-08	1.56e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—hematologic cancer	9.74e-08	1.56e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EP300—hematologic cancer	9.71e-08	1.55e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CD—hematologic cancer	9.66e-08	1.54e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—hematologic cancer	9.6e-08	1.53e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—hematologic cancer	9.59e-08	1.53e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—hematologic cancer	9.58e-08	1.53e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—hematologic cancer	9.54e-08	1.52e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—hematologic cancer	9.53e-08	1.52e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—hematologic cancer	9.49e-08	1.52e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—hematologic cancer	9.45e-08	1.51e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—hematologic cancer	9.44e-08	1.51e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SRC—hematologic cancer	9.44e-08	1.51e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—hematologic cancer	9.42e-08	1.51e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—hematologic cancer	9.42e-08	1.51e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—hematologic cancer	9.41e-08	1.5e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—hematologic cancer	9.39e-08	1.5e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—hematologic cancer	9.33e-08	1.49e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JUN—hematologic cancer	9.31e-08	1.49e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—hematologic cancer	9.22e-08	1.47e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—hematologic cancer	9.19e-08	1.47e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3R1—hematologic cancer	9.12e-08	1.46e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—hematologic cancer	9.1e-08	1.45e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—hematologic cancer	9.1e-08	1.45e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—hematologic cancer	9.08e-08	1.45e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—hematologic cancer	9.08e-08	1.45e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—hematologic cancer	9.08e-08	1.45e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—hematologic cancer	9.07e-08	1.45e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1A—hematologic cancer	9.03e-08	1.44e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK3—hematologic cancer	9.02e-08	1.44e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTEN—hematologic cancer	9.01e-08	1.44e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—hematologic cancer	8.95e-08	1.43e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK8—hematologic cancer	8.81e-08	1.41e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—hematologic cancer	8.78e-08	1.4e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—hematologic cancer	8.76e-08	1.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—hematologic cancer	8.75e-08	1.4e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—hematologic cancer	8.71e-08	1.39e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK3—hematologic cancer	8.7e-08	1.39e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—hematologic cancer	8.69e-08	1.39e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—hematologic cancer	8.69e-08	1.39e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—hematologic cancer	8.65e-08	1.38e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—hematologic cancer	8.62e-08	1.38e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EP300—hematologic cancer	8.59e-08	1.37e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—hematologic cancer	8.47e-08	1.35e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—hematologic cancer	8.46e-08	1.35e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—hematologic cancer	8.44e-08	1.35e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CB—hematologic cancer	8.42e-08	1.35e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—hematologic cancer	8.4e-08	1.34e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—hematologic cancer	8.38e-08	1.34e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—hematologic cancer	8.34e-08	1.33e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—hematologic cancer	8.32e-08	1.33e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—hematologic cancer	8.28e-08	1.32e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ABCB1—hematologic cancer	8.23e-08	1.31e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—hematologic cancer	8.14e-08	1.3e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—hematologic cancer	8.11e-08	1.3e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—hematologic cancer	8.1e-08	1.29e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—hematologic cancer	8.06e-08	1.29e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—hematologic cancer	8.04e-08	1.28e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—hematologic cancer	8.04e-08	1.28e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—hematologic cancer	8.03e-08	1.28e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NCOR1—hematologic cancer	7.99e-08	1.28e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—hematologic cancer	7.99e-08	1.28e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—hematologic cancer	7.98e-08	1.27e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—hematologic cancer	7.92e-08	1.27e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—hematologic cancer	7.81e-08	1.25e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—hematologic cancer	7.76e-08	1.24e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—hematologic cancer	7.72e-08	1.23e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK3—hematologic cancer	7.7e-08	1.23e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—hematologic cancer	7.64e-08	1.22e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—hematologic cancer	7.49e-08	1.2e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—hematologic cancer	7.47e-08	1.19e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—hematologic cancer	7.45e-08	1.19e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—hematologic cancer	7.41e-08	1.18e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—hematologic cancer	7.31e-08	1.17e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTEN—hematologic cancer	7.28e-08	1.16e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—hematologic cancer	7.21e-08	1.15e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—hematologic cancer	7.18e-08	1.15e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—hematologic cancer	7.16e-08	1.14e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—hematologic cancer	7.06e-08	1.13e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—hematologic cancer	7.04e-08	1.13e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—hematologic cancer	6.95e-08	1.11e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—EP300—hematologic cancer	6.94e-08	1.11e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—hematologic cancer	6.92e-08	1.11e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—hematologic cancer	6.89e-08	1.1e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—hematologic cancer	6.79e-08	1.09e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—hematologic cancer	6.64e-08	1.06e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—hematologic cancer	6.6e-08	1.05e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—hematologic cancer	6.36e-08	1.02e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—hematologic cancer	6.36e-08	1.02e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—hematologic cancer	6.15e-08	9.82e-07	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—hematologic cancer	6.09e-08	9.72e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—hematologic cancer	5.93e-08	9.48e-07	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—hematologic cancer	5.88e-08	9.39e-07	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—hematologic cancer	5.87e-08	9.37e-07	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—hematologic cancer	5.63e-08	8.99e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CREBBP—hematologic cancer	5.5e-08	8.79e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.21e-08	8.33e-07	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—hematologic cancer	5.19e-08	8.3e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—hematologic cancer	5.15e-08	8.22e-07	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—hematologic cancer	5.13e-08	8.2e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3R1—hematologic cancer	4.92e-08	7.87e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CB—hematologic cancer	4.55e-08	7.26e-07	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—hematologic cancer	4.19e-08	6.7e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTEN—hematologic cancer	3.93e-08	6.27e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—EP300—hematologic cancer	3.75e-08	5.98e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.77e-08	4.43e-07	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—hematologic cancer	2.26e-08	3.62e-07	CbGpPWpGaD
